ClinicalTrials.Veeva

Menu

Distal Venous Arterialisation of Ischemic Limb

C

Clinical Centre of Serbia

Status and phase

Unknown
Phase 3
Phase 2

Conditions

Critical Limb Ischemia

Treatments

Drug: Aspirin
Procedure: distal venous arterialisation

Study type

Interventional

Funder types

Other

Identifiers

NCT01211925
440/III-3

Details and patient eligibility

About

Distal venous arterialisation (DVA) improve outcome in patients with nonreconstructible peripheral arterial occlusive disease.

Full description

The aim of this study was to estimate validity of distal venous arterialisation (DVA) as a limb salvage procedure. This prospective randomized study reported early results of 30 unreconstructible patients with critical limb ischemia (CLI) treated during 2009 year at Clinic for vascular surgery, Clinical Center of Serbia in Belgrade. Patients were divided in two groups, 10 treated with DVA and 20 conservatively (CT) using antiplatelet drugs.

Enrollment

30 patients

Sex

All

Ages

20 to 95 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Absence of any possibility for direct revascularisation due to extensive occlusive disease of crural and pedal arteries
  • Sufficient deep venous system and usable great saphenous vein as a graft for in situ bypass surgery according duplex scanning
  • localized infective of necrotic process up to the metatarsal level
  • Satisfactory general patient condition

Exclusion criteria

  • advanced lower limb ischemia
  • venous insufficiency of lower limb

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

30 participants in 2 patient groups

critical ischemia
Experimental group
Treatment:
Procedure: distal venous arterialisation
Control
No Intervention group
Description:
Best medical treatment
Treatment:
Drug: Aspirin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems